22 results on '"Verboom, M."'
Search Results
2. Five-Year Results of an IgA and IgM-Enriched Human Immunoglobulin G-Based Therapy for Early Anti-HLA Donor Specific Antibodies in 158 Lung-Transplanted Patients
3. Five-Year Results of an IgA- and IgM-Enriched Human Immunoglobulin-Based Therapy for Early anti-HLA Donor-Specific Antibodies after Lung Transplantation
4. Long-term Results of an IgM-enriched Human Immunoglobulin-based Therapy for Early Donor Specific Antibodies After Lung Transplantation
5. Long-term Results of an IgM-Enriched Human Immunoglobulin-Based Therapy for Early Donor-Specific Antibodies after Lung Transplantation
6. Three Years Experience with an IgM Enriched Human Intravenous Immunoglobulins Based Treatment for Patients with Early Donor Specific Antibodies After Lung Transplantation
7. Three Years of Experience with an IgM-Enriched Human Intravenous Immunoglobulin-Based Treatment for Patients with Early Donor-Specific Anti-HLA Antibodies after Lung Transplantation
8. Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib
9. Donor specific antibodies are associated with higher inflammatory activity, more fibrosis and higher expression of rejection associated transcripts in human liver allografts with subclinical rejection
10. Evolving Risk Factors for Mortality after Lung Transplantation over the Last 10 Years: Insights from a Single-Centre Database
11. IgM Enriched Human Immunoglobulins and Rituximab Nullify the Mortality Risk Associated with Early Donor Specific Antibodies After Lung Transplantation
12. Risk Factors and Impact of Bronchial Stenoses after Lung Transplantation: Ten Year Single Center Experience with over 1,100 Patients
13. IgM Enriched Human Intravenous Immunoglobulins Based Treatment of Patients with Early Donor Specific Anti-HLA Antibodies after Lung Transplantation
14. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
15. Identifying Biological and Clinical Characteristics of Patients with Gastrointestinal Stromal Tumours (Gist) Responding to Imatinib Therapy for More Than 5 and 10 Years
16. Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction
17. The new HLA allele, HLA-A*03:57, differs from HLA-A*03:01 by two amino acids at positions 76 and 77 in the α2 domain affecting the pocket F of the peptide-binding groove
18. DQB1*0323 is the result of a gene conversion event between a DQB1*06 and a DQB1*030303 allele
19. Bioinformatic integration of biomechanics makes HLA sequencing universally applicable
20. The nature of diversity of HLA‐DRB1 exon 3
21. Sequence analysis of the novel allele HLA-B*070502+
22. HLA-A*2313 is closest to A*2301 but is likely to stimulate T cells when mismatcheda
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.